Bavarian Nordic
Bavarian Nordic A/S, a leading biotechnology company headquartered in Denmark (DK), is renowned for its innovative approach in the field of immunotherapy and vaccine development. Founded in 1994, the company has made significant strides in combating infectious diseases and cancer, with a strong operational presence across Europe and North America. Specialising in the development of live virus vaccines and immunotherapies, Bavarian Nordic's core products include the smallpox vaccine, IMVAMUNE®, and the cancer immunotherapy candidate, BN-Brachyury. These offerings are distinguished by their unique mechanisms and robust safety profiles, positioning the company as a key player in the biopharmaceutical industry. With a commitment to advancing public health, Bavarian Nordic has achieved notable milestones, including partnerships with global health organisations, solidifying its reputation as a trusted innovator in vaccine technology.
DitchCarbon Score
How does Bavarian Nordic's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bavarian Nordic's score of 8 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Bavarian Nordic's reported carbon emissions
In 2023, Bavarian Nordic reported total carbon emissions of approximately 10,068,000 kg CO2e, comprising about 4,364,000 kg CO2e from Scope 1 and about 6,318,000 kg CO2e from Scope 2 emissions. This marks a significant increase in emissions compared to previous years, with total emissions in 2022 being about 2,753,000 kg CO2e. Over the years, Bavarian Nordic has shown a fluctuating trend in emissions. For instance, in 2021, the company emitted approximately 2,506,000 kg CO2e, while in 2020, emissions were about 2,556,000 kg CO2e. The company has not set specific reduction targets or committed to net-zero emissions as of the latest data, but it is classified as "Committed" to near-term targets. Bavarian Nordic operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector and is headquartered in Denmark. The company continues to monitor its carbon footprint and engage in sustainability practices, although specific reduction initiatives have not been detailed in the available data.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 2,178,000 | 0,000,000 | 000,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 3,103,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bavarian Nordic is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
